Andrei Breazna

3.7k total citations
30 papers, 2.7k citations indexed

About

Andrei Breazna is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Andrei Breazna has authored 30 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 13 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Economics and Econometrics. Recurrent topics in Andrei Breazna's work include Lipoproteins and Cardiovascular Health (24 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Andrei Breazna is often cited by papers focused on Lipoproteins and Cardiovascular Health (24 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (12 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Andrei Breazna collaborates with scholars based in United States, United Kingdom and Netherlands. Andrei Breazna's co-authors include David A. DeMicco, John J.P. Kastelein, Prakash Deedwania, James Shepherd, David D. Waters, Philip J. Barter, Nanette K. Wenger, David D. Waters, Vera Bittner and Chuan‐Chuan Wun and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Andrei Breazna

29 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrei Breazna United States 22 1.6k 998 827 456 313 30 2.7k
Jane Armitage United Kingdom 11 1.8k 1.1× 1.5k 1.5× 961 1.2× 514 1.1× 239 0.8× 29 3.4k
Adriaan M. Kamper Netherlands 17 2.0k 1.2× 821 0.8× 826 1.0× 771 1.7× 368 1.2× 26 3.2k
Athanasios A. Papageorgiou Greece 26 1.5k 0.9× 1.1k 1.1× 814 1.0× 384 0.8× 179 0.6× 46 2.7k
David A. DeMicco United States 33 2.6k 1.6× 1.8k 1.8× 1.5k 1.8× 600 1.3× 459 1.5× 69 4.5k
Stephen D. Wiviott United States 28 1.6k 1.0× 1.4k 1.4× 1.4k 1.7× 464 1.0× 287 0.9× 68 3.5k
Michel Komajda France 13 1.7k 1.0× 1.7k 1.7× 1.0k 1.3× 233 0.5× 170 0.5× 25 3.5k
Teik Chye Ooi Canada 27 1.2k 0.7× 1.0k 1.0× 633 0.8× 189 0.4× 323 1.0× 79 2.4k
Na‐Qiong Wu China 31 1.9k 1.2× 1.1k 1.1× 1.2k 1.5× 193 0.4× 167 0.5× 192 3.3k
S. Féasson France 4 3.7k 2.3× 1.5k 1.5× 1.6k 2.0× 1.2k 2.7× 287 0.9× 6 5.4k
Michael C dʼEmden Australia 22 2.4k 1.5× 2.9k 2.9× 1.1k 1.3× 468 1.0× 387 1.2× 72 5.4k

Countries citing papers authored by Andrei Breazna

Since Specialization
Citations

This map shows the geographic impact of Andrei Breazna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrei Breazna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrei Breazna more than expected).

Fields of papers citing papers by Andrei Breazna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrei Breazna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrei Breazna. The network helps show where Andrei Breazna may publish in the future.

Co-authorship network of co-authors of Andrei Breazna

This figure shows the co-authorship network connecting the top 25 collaborators of Andrei Breazna. A scholar is included among the top collaborators of Andrei Breazna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrei Breazna. Andrei Breazna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ezekowitz, Michael D., Charles V. Pollack, Paul W. Sanders, et al.. (2016). Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. American Heart Journal. 179. 59–68. 24 indexed citations
2.
Shepherd, James, Andrei Breazna, Prakash Deedwania, et al.. (2016). Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 117(8). 1199–1205. 14 indexed citations
3.
Langslet, Gisle, Andrei Breazna, & Euridiki Drogari. (2016). A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 10(5). 1153–1162.e3. 24 indexed citations
4.
Lee, Theodore, Cristina Masseria, Andrei Breazna, et al.. (2016). HOSPITALIZATIONS, RECURRENT VENOUS THROMBOEMBOLISM OR VENOUS THROMBOEMBOLISM-RELATED DEATH, AND MAJOR BLEEDING, BY INDEX EVENT FROM THE AMPLIFY TRIAL. Journal of the American College of Cardiology. 67(13). 2256–2256. 1 indexed citations
5.
Bangalore, Sripal, Andrei Breazna, David A. DeMicco, Chuan‐Chuan Wun, & Franz H. Messerli. (2015). Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. Journal of the American College of Cardiology. 65(15). 1539–1548. 161 indexed citations
6.
Deedwania, Prakash, J. Shepherd, Andrei Breazna, & David A. DeMicco. (2015). Effect of high‐dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the T reating to N ew T argets ( TNT ) study. Diabetes Obesity and Metabolism. 18(1). 56–63. 8 indexed citations
7.
Ho, Jennifer E., David D. Waters, Daniel J. Wilson, et al.. (2012). Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 109(12). 1761–1766. 9 indexed citations
8.
Waters, David D., Jennifer E. Ho, S. Matthijs Boekholdt, et al.. (2012). Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy. Journal of the American College of Cardiology. 61(2). 148–152. 133 indexed citations
9.
Waters, David D., Jennifer E. Ho, David A. DeMicco, et al.. (2011). Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Journal of the American College of Cardiology. 57(14). 1535–1545. 246 indexed citations
10.
11.
12.
LaRosa, John C., Prakash Deedwania, James Shepherd, et al.. (2009). Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial). The American Journal of Cardiology. 105(3). 283–287. 46 indexed citations
13.
Willavize, Susan, Miia Kivipelto, David L. Sparks, et al.. (2009). P1‐260: Disease progression of cognitive impairment in Alzheimer's disease: A model‐based approach. Alzheimer s & Dementia. 5(4S_Part_8). 1 indexed citations
14.
Jones, Roy, Miia Kivipelto, Howard Feldman, et al.. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer s & Dementia. 4(2). 145–153. 53 indexed citations
15.
Shepherd, James, John J.P. Kastelein, Vera Bittner, et al.. (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. Journal of the American College of Cardiology. 51(15). 1448–1454. 229 indexed citations
16.
Shah, Sanjiv J., David D. Waters, Philip J. Barter, et al.. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology. 51(20). 1938–1943. 70 indexed citations
17.
Kostis, John B., Andrei Breazna, Prakash Deedwania, & John C. LaRosa. (2008). The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. Journal of Clinical Hypertension. 10(5). 367–376. 12 indexed citations
18.
19.
Shepherd, James, John J.P. Kastelein, Vera Bittner, et al.. (2007). Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease. Clinical Journal of the American Society of Nephrology. 2(6). 1131–1139. 198 indexed citations
20.
Waters, David D., John C. LaRosa, Philip J. Barter, et al.. (2006). Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. Journal of the American College of Cardiology. 48(9). 1793–1799. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jane Armitage Breakdown of academic impact, for papers by Adriaan M. Kamper Breakdown of academic impact, for papers by Athanasios A. Papageorgiou Breakdown of academic impact, for papers by David A. DeMicco Breakdown of academic impact, for papers by Stephen D. Wiviott Breakdown of academic impact, for papers by Michel Komajda Breakdown of academic impact, for papers by Teik Chye Ooi Breakdown of academic impact, for papers by Na‐Qiong Wu Breakdown of academic impact, for papers by S. Féasson Breakdown of academic impact, for papers by Michael C dʼEmden
Rankless by CCL
2026